{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:49:18Z","timestamp":1772160558201,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"NIH","award":["DK069350"],"award-info":[{"award-number":["DK069350"]}]},{"name":"FDA","award":["02525"],"award-info":[{"award-number":["02525"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ecl.2018.07.013","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T12:19:44Z","timestamp":1541074784000},"page":"901-915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["New Directions in Treatment of Hypoparathyroidism"],"prefix":"10.1016","volume":"47","author":[{"given":"Gaia","family":"Tabacco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ecl.2018.07.013_bib1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1172\/JCI100224","article-title":"Studies on the physiology of the parathyroid glands","volume":"7","author":"Albright","year":"1929","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.ecl.2018.07.013_bib2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1056\/NEJM196701192760304","article-title":"Antibodies and clinical resistance to parathyroid hormone","volume":"276","author":"Melick","year":"1967","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2018.07.013_bib3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","article-title":"Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism","author":"Winer","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2018.07.013_bib4","unstructured":"United States Food and Drug Administration. NATPARA package insert. 2015. 435518. Available at: http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ucm435518.htm. Accessed May 9, 2016."},{"issue":"4","key":"10.1016\/j.ecl.2018.07.013_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human\u00a0parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study","volume":"1","author":"Mannstadt","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ecl.2018.07.013_bib6","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00198-009-1149-x","article-title":"Therapy of hypoparathyroidism with intact parathyroid hormone","author":"Rubin","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2018.07.013_bib7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12020-016-1141-0","article-title":"Effects of parathyroid hormone rhPTH(1\u201384) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study","author":"Clarke","year":"2017","journal-title":"Endocrine"},{"issue":"10","key":"10.1016\/j.ecl.2018.07.013_bib8","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study","volume":"26","author":"Sikjaer","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2018.07.013_bib9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4158\/EP15936.OR","article-title":"An open-label extension study of parathyroid hormone RHPTH(1-84) in adults with hypoparathyroidism","author":"Lakatos","year":"2016","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.ecl.2018.07.013_bib10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1210\/jc.2012-2984","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety","volume":"98","author":"Cusano","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ecl.2018.07.013_bib11","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1210\/jc.2015-4135","article-title":"Therapy of hypoparathyroidism with PTH(1\u201384): a prospective six year investigation of efficacy and safety","volume":"101","author":"Rubin","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2018.07.013_bib12","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.clinthera.2014.04.001","article-title":"Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase i study","volume":"36","author":"Clarke","year":"2014","journal-title":"Clin Ther"},{"issue":"10","key":"10.1016\/j.ecl.2018.07.013_bib13","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/jbmr.1964","article-title":"PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6\u00a0months of treatment","volume":"28","author":"Sikjaer","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2018.07.013_bib14","unstructured":"Fox J, Wells D, Garceau R. Relationships between pharmacokinetic profile of human PTH(1-84) and serum calcium response in postmenopausal women following four different methods of administration. Program of the 33rd Annual Meeting of the American Society of Bone and Mineral Research. San Diego (CA), 2011."},{"issue":"10","key":"10.1016\/j.ecl.2018.07.013_bib15","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.clinthera.2017.08.011","article-title":"Safety and efficacy of recombinant human parathyroid hormone in adults with hypoparathyroidism randomly assigned to receive fixed 25-\u03bcg or 50-\u03bcg daily doses","volume":"39","author":"Bilezikian","year":"2017","journal-title":"Clin Ther"},{"issue":"6","key":"10.1016\/j.ecl.2018.07.013_bib16","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1210\/jc.2015-3907","article-title":"Management of hypoparathyroidism: summary statement and guidelines","volume":"101","author":"Brandi","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2018.07.013_bib17","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fendo.2016.00172","article-title":"Review of hypoparathyroidism","volume":"7","author":"Abate","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10.1016\/j.ecl.2018.07.013_bib18","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1210\/jc.2015-3910","article-title":"Management of hypoparathyroidism: present and future","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2018.07.013_bib19","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/jbmr.1493","article-title":"Changes in 3-dimensional bone structure indices in hypoparathyroid patients treated with PTH(1-84): a randomized controlled study","volume":"27","author":"Sikjaer","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"issue":"11","key":"10.1016\/j.ecl.2018.07.013_bib20","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1002\/jbmr.452","article-title":"PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism","volume":"26","author":"Rubin","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"issue":"5","key":"10.1016\/j.ecl.2018.07.013_bib21","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/jbmr.2777","article-title":"Effects of parathyroid hormone administration on bone strength in hypoparathyroidism","volume":"31","author":"Rubin","year":"2016","journal-title":"J\u00a0Bone Miner Res"},{"issue":"2","key":"10.1016\/j.ecl.2018.07.013_bib22","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s12020-016-1101-8","article-title":"Skeletal changes after restoration of the euparathyroid state in patients with hypoparathyroidism and primary hyperparathyroidism","volume":"55","author":"Cipriani","year":"2017","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.ecl.2018.07.013_bib23","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jbmr.2588","article-title":"PTH(1-84) Administration in hypoparathyroidism transiently reduces bone matrix mineralization","volume":"31","author":"Misof","year":"2016","journal-title":"J\u00a0Bone Miner Res"},{"issue":"2","key":"10.1016\/j.ecl.2018.07.013_bib24","first-page":"391","article-title":"Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism","volume":"97","author":"Winer","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2018.07.013_bib25","doi-asserted-by":"crossref","first-page":"17055","DOI":"10.1038\/nrdp.2017.55","article-title":"Hypoparathyroidism","volume":"3","author":"Mannstadt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.ecl.2018.07.013_bib26","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1210\/jc.2017-01471","article-title":"Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism","volume":"103","author":"Vokes","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ecl.2018.07.013_bib27","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1210\/jc.2014-2267","article-title":"PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy","volume":"99","author":"Cusano","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2018.07.013_bib28","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1210\/jc.2013-1239","article-title":"The effect of PTH(1-84) on quality of life in hypoparathyroidism","volume":"98","author":"Cusano","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2018.07.013_bib29","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00198-014-2677-6","article-title":"Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial","volume":"25","author":"Sikjaer","year":"2014","journal-title":"Osteoporos Int"},{"issue":"10","key":"10.1016\/j.ecl.2018.07.013_bib30","first-page":"3480","article-title":"A\u00a0randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism","volume":"83","author":"Winer","year":"1998","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ecl.2018.07.013_bib31","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/jc.2002-021736","article-title":"Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium","volume":"88","author":"Winer","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2018.07.013_bib32","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1210\/jc.2009-2464","article-title":"Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium","volume":"95","author":"Winer","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2018.07.013_bib33","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jpeds.2014.04.060","article-title":"Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism","volume":"165","author":"Winer","year":"2014","journal-title":"J\u00a0Pedriatr"},{"issue":"9","key":"10.1016\/j.ecl.2018.07.013_bib34","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1210\/jc.2007-2552","article-title":"Effects of once versus twice-daily parathyroid hormone 1\u201334 therapy in children with hypoparathyroidism","volume":"93","author":"Winer","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ecl.2018.07.013_bib35","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1210\/jc.2015-1855","article-title":"PTH(1-34) for surgical hypoparathyroidism: a prospective, open-label investigation of efficacy and quality of life","volume":"100","author":"Santonati","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2018.07.013_bib36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1210\/jc.2017-01555","article-title":"PTH(1\u201334) for surgical hypoparathyroidism: a 2-year prospective, open-label investigation of efficacy and quality of life","volume":"103","author":"Palermo","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ecl.2018.07.013_bib37","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jbmr.1627","article-title":"Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure","volume":"27","author":"Gafni","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"issue":"7","key":"10.1016\/j.ecl.2018.07.013_bib38","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/01926230601072301","article-title":"Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats","volume":"34","author":"Jolette","year":"2006","journal-title":"Toxicol Pathol"},{"issue":"3","key":"10.1016\/j.ecl.2018.07.013_bib39","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol"},{"issue":"12","key":"10.1016\/j.ecl.2018.07.013_bib40","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/jbmr.1800","article-title":"Safety of osteoanabolic therapy: a decade of experience","volume":"27","author":"Capriani","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"issue":"12","key":"10.1016\/j.ecl.2018.07.013_bib41","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1002\/jbmr.1768","article-title":"The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years","volume":"27","author":"Andrews","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"issue":"1","key":"10.1016\/j.ecl.2018.07.013_bib42","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/jbmr.2917","article-title":"Prolonged pharmacokinetic and pharmacodynamic actions of a pegylated parathyroid hormone (1-34) peptide fragment","volume":"32","author":"Guo","year":"2017","journal-title":"J\u00a0Bone Miner Res"},{"issue":"7","key":"10.1016\/j.ecl.2018.07.013_bib43","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/jbmr.2811","article-title":"Pharmacodynamic actions of a long-acting PTH analog (LA-PTH) in thyroparathyroidectomized (TPTX) rats and normal monkeys","volume":"31","author":"Shimizu","year":"2016","journal-title":"J\u00a0Bone Miner Res"},{"issue":"5","key":"10.1016\/j.ecl.2018.07.013_bib44","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/jbmr.2769","article-title":"Diphtheria toxin- and GFP-based mouse models of acquired hypoparathyroidism and treatment with a long-acting parathyroid hormone analog","volume":"31","author":"Bi","year":"2016","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2018.07.013_bib45","doi-asserted-by":"crossref","unstructured":"Karpf DB, Mortensen E, Sprogoe K, et\u00a0al. The design and preliminary results of a phase 1 TransCon PTH trial in healthy volunteers. Program of 100th Annual meeting of the Endocrine society. Endocrine Reviews. Chicago (IL), 2018.","DOI":"10.1530\/endoabs.56.GP174"},{"issue":"3","key":"10.1016\/j.ecl.2018.07.013_bib46","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1530\/JME-16-0124","article-title":"Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis","volume":"57","author":"Hannan","year":"2016","journal-title":"J\u00a0Mol Endocrinol"},{"issue":"5","key":"10.1016\/j.ecl.2018.07.013_bib47","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1359\/jbmr.081233","article-title":"PTH(1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation","volume":"24","author":"Theman","year":"2009","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2018.07.013_bib48","first-page":"1","article-title":"Calcimimetic and calcilytic therapies for inherited disorders of the calcium-sensing receptor signalling pathway","author":"Hannan","year":"2017","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.ecl.2018.07.013_bib49","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00223-015-0052-z","article-title":"Calcimimetic and calcilytic drugs: feats, flops, and futures","volume":"98","author":"Nemeth","year":"2016","journal-title":"Calcif Tissue Int"},{"issue":"9","key":"10.1016\/j.ecl.2018.07.013_bib50","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1210\/en.2015-1269","article-title":"The calcilytic agent NPS 2143 rectifies hypocalcemia in a mouse model with an activating calcium-sensing receptor (CaSR) mutation: relevance to autosomal dominant hypocalcemia type 1 (ADH1)","volume":"156","author":"Hannan","year":"2015","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.ecl.2018.07.013_bib51","doi-asserted-by":"crossref","first-page":"e91103","DOI":"10.1172\/jci.insight.91103","article-title":"G\u03b111 mutation in mice causes hypocalcemia rectifiable by calcilytic therapy","volume":"2","author":"Gorvin","year":"2017","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.ecl.2018.07.013_bib52","doi-asserted-by":"crossref","first-page":"e91079","DOI":"10.1172\/jci.insight.91079","article-title":"Knockin mouse with mutant G\u03b111mimics human inherited hypocalcemia and is rescued by pharmacologic inhibitors","volume":"2","author":"Roszko","year":"2017","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.ecl.2018.07.013_bib53","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/jbmr.2551","article-title":"Calcilytic ameliorates abnormalities of mutant Calcium-Sensing Receptor (CaSR) knock-in mice mimicking autosomal dominant hypocalcemia (ADH)","volume":"30","author":"Dong","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2018.07.013_bib54","unstructured":"Ramnitz M, Gafni RI, Brillante B, et al. Treatment of autosomal dominant hypocalcemia with the calcilytic NPSP795. Program of the 37th Annual Meeting of the American Society of Bone and Mineral Research. Seattle (WA), 2015."}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852918305577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852918305577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:45:13Z","timestamp":1760175913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852918305577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0889852918305577"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2018.07.013","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Directions in Treatment of Hypoparathyroidism","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2018.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}